- Immunome Inc IMNM has announced that its three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against COVI-19 Delta variant in pre-clinical pseudovirus testing.
- Furthermore, IMM-BCP-01 showed in-vitro activity via non-neutralizing mechanisms, such as complement fixation, which Immunome expects will enable viral clearance.
- Immunome was awarded a $17.6 million technology award from the U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense, collaborating with the Defense Health Agency to support the COVID program.
- The Company plans to submit an IND application with the FDA in 3Q of 2021.
- Price Action: IMNM shares are up 32.70% at $22.05 during the premarket session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
